• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Adding molecular data to prognostic models can improve predictive power in treated patients with myelodysplastic syndromes.

作者信息

Nazha A, Al-Issa K, Hamilton B K, Radivoyevitch T, Gerds A T, Mukherjee S, Adema V, Zarzour A, Abuhadra N, Patel B J, Hirsch C M, Advani A, Przychodzen B, Carraway H E, Maciejewski J P, Sekeres M A

机构信息

Leukemia Program, Department of Hematology and Oncology, Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH, USA.

Department of Translational Hematology and Oncology Research, Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH, USA.

出版信息

Leukemia. 2017 Dec;31(12):2848-2850. doi: 10.1038/leu.2017.266. Epub 2017 Aug 18.

DOI:10.1038/leu.2017.266
PMID:28819282
Abstract
摘要

相似文献

1
Adding molecular data to prognostic models can improve predictive power in treated patients with myelodysplastic syndromes.将分子数据添加到预后模型中可以提高接受治疗的骨髓增生异常综合征患者的预测能力。
Leukemia. 2017 Dec;31(12):2848-2850. doi: 10.1038/leu.2017.266. Epub 2017 Aug 18.
2
Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents.甲基化抑制剂治疗的骨髓增生异常综合征中TP53突变的临床意义
Oncotarget. 2016 Mar 22;7(12):14172-87. doi: 10.18632/oncotarget.7290.
3
Might arsenic trioxide be useful in the treatment of advanced myelodysplastic syndromes?三氧化二砷对晚期骨髓增生异常综合征的治疗可能有效吗？
Haematologica. 2000 Sep;85(9):1002-3.
4
High levels of Ca(2+)-independent endonuclease activity capable of producing nucleosomal-size DNA fragmentation in non-adherent marrow mononuclear cells from patients with myelodysplastic syndromes and acute myelogenous leukemia.在骨髓增生异常综合征和急性髓性白血病患者的非贴壁骨髓单个核细胞中，高水平的不依赖钙离子的核酸内切酶活性能够产生核小体大小的DNA片段化。
Leukemia. 1996 Jan;10(1):67-73.
5
Genome-wide miRNA profiling in myelodysplastic syndrome with del(5q) treated with lenalidomide.来那度胺治疗的伴有5号染色体长臂缺失（del(5q)）的骨髓增生异常综合征的全基因组miRNA分析
Eur J Haematol. 2015 Jul;95(1):35-43. doi: 10.1111/ejh.12458. Epub 2014 Nov 11.
6
[Myelodysplastic syndromes (MDS) and their evolution].[骨髓增生异常综合征（MDS）及其演变]
Rinsho Ketsueki. 1987 Aug;28(8):1354-60.
7
[Efficiency of cyclosporin A therapy in patients with myelodysplastic syndrome].[环孢素A治疗骨髓增生异常综合征患者的疗效]
Ter Arkh. 2010;82(8):48-53.
8
Improving Prognostic Modeling in Myelodysplastic Syndromes.改善骨髓增生异常综合征的预后模型
Curr Hematol Malig Rep. 2016 Dec;11(6):395-401. doi: 10.1007/s11899-016-0342-1.
9
Outcome of patients with low-risk and intermediate-1-risk myelodysplastic syndrome after hypomethylating agent failure: a report on behalf of the MDS Clinical Research Consortium.低甲基化药物治疗失败后低危和中危-1骨髓增生异常综合征患者的结局：代表骨髓增生异常综合征临床研究联盟的报告
Cancer. 2015 Mar 15;121(6):876-82. doi: 10.1002/cncr.29145. Epub 2014 Nov 19.
10
[Prognostic factors in the myelodysplastic syndromes].[骨髓增生异常综合征的预后因素]
Rinsho Ketsueki. 1988 Aug;29(8):1214-8.

引用本文的文献

1
Threefold IPSS-M reclassification outperforms original stratification in predicting post-transplant outcomes for MDS patients.在预测骨髓增生异常综合征（MDS）患者移植后结局方面，IPSS-M三分法重新分类优于原始分层。
Cell Transplant. 2025 Jan-Dec;34:9636897251348406. doi: 10.1177/09636897251348406. Epub 2025 Jun 24.
2
[Application of the variant allele frequency of myeloid-associated gene mutations in myelodysplastic syndrome].[髓系相关基因突变的变异等位基因频率在骨髓增生异常综合征中的应用]
Zhonghua Xue Ye Xue Za Zhi. 2025 Apr 14;46(4):372-376. doi: 10.3760/cma.j.cn121090-20240806-00293.
3
Prognostic impact of next-generation sequencing on myelodysplastic syndrome: A single-center experience.
基于新一代测序的骨髓增生异常综合征预后影响：一项单中心经验。
Medicine (Baltimore). 2024 Oct 11;103(41):e39909. doi: 10.1097/MD.0000000000039909.
4
Artificial intelligence-based Myelodysplastic Syndromes Score, 2022 classifications, and the Molecular International Prognostic Scoring System: a perfect match.基于人工智能的骨髓增生异常综合征评分、2022年分类以及分子国际预后评分系统：完美匹配。
Haematologica. 2025 Feb 1;110(2):536-539. doi: 10.3324/haematol.2024.286340.
5
Validation of the molecular international prognostic scoring system in patients with myelodysplastic syndromes defined by international consensus classification.通过国际共识分类定义的骨髓增生异常综合征患者中分子国际预后评分系统的验证。
Blood Cancer J. 2023 Aug 9;13(1):120. doi: 10.1038/s41408-023-00894-8.
6
Evaluation of new IPSS-Molecular model and comparison of different prognostic systems in patients with myelodysplastic syndrome.骨髓增生异常综合征患者新IPSS分子模型的评估及不同预后系统的比较
Blood Sci. 2023 Jul 5;5(3):187-195. doi: 10.1097/BS9.0000000000000166. eCollection 2023 Jul.
7
Genomic Stratification of Hematological Malignancies.血液系统恶性肿瘤的基因组分层
Hemasphere. 2023 May 25;7(6):e902. doi: 10.1097/HS9.0000000000000902. eCollection 2023 Jun.
8
Assessment and validation of the molecular international prognostic scoring system for myelodysplastic syndromes.评估和验证骨髓增生异常综合征的分子国际预后评分系统。
Leukemia. 2023 Jul;37(7):1530-1539. doi: 10.1038/s41375-023-01910-3. Epub 2023 May 5.
9
Understanding the Continuum between High-Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia.理解高危骨髓增生异常综合征与急性髓系白血病之间的连续统。
Int J Mol Sci. 2023 Mar 6;24(5):5018. doi: 10.3390/ijms24055018.
10
Risk stratifying MDS in the time of precision medicine.精准医学时代的 MDS 风险分层。
Hematology Am Soc Hematol Educ Program. 2022 Dec 9;2022(1):375-381. doi: 10.1182/hematology.2022000349.